We advised ADC Therapeutics on its offering of shares and pre-funded warrants

Davis Polk advised ADC Therapeutics SA in connection with a SEC-registered offering of 13,411,912 of its common shares and pre-funded warrants to purchase 8,163,265 common shares. ADC Therapeutics is listed on the NYSE under the ticker symbol “ADCT.”

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates David Li and Sierra M. Acosta. Partner Kara L. Mungovan and associate Michelle Zhao provided tax advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post